Background
Prospective phase II, N=51, locoregionally recurrent ovarian, fallopian tube, or primary peritoneal cancer previously treated with surgery and chemotherapy. Evaluates feasibility and efficacy of IMRT for isolated locoregional recurrence.
Interventions and follow up
Treatment: IMRT to isolated pelvic/paraaortic recurrence ± concurrent chemotherapy
Primary endpoint: Local control, symptom palliation, toxicity
mFollow up: Not reported
Primary endpoint: Local control, symptom palliation, toxicity
mFollow up: Not reported
Results
3-yr locoregional control: 52%
3-yr OS: 52%
3-yr PFS: 35%
Grade ≥3 late toxicity: 12% (bowel/bladder)
3-yr OS: 52%
3-yr PFS: 35%
Grade ≥3 late toxicity: 12% (bowel/bladder)
Adverse events
Grade 3 acute GI: 10%
Grade 3 acute GU: 4%
Late grade ≥3: 12%
Bowel obstruction requiring intervention: 4%
Grade 3 acute GU: 4%
Late grade ≥3: 12%
Bowel obstruction requiring intervention: 4%
Conclusions
Salvage IMRT for isolated locoregionally recurrent ovarian cancer provides durable locoregional control (52% at 3 yr) and OS (52% at 3 yr) with acceptable toxicity in a heavily pretreated population, supporting a role in carefully selected patients.
Key Limitations
Single-arm phase II, no comparator; small sample (N=51); heterogeneous recurrence sites and prior therapy; selection bias toward isolated locoregional disease; follow-up duration not reported.
Clinical Context
Supports IMRT as a local-control/palliative option for isolated locoregional ovarian cancer recurrence when systemic options are limited; complements PARP inhibitor and surgical strategies in multidisciplinary management.